1-[(9-deazaadenin-9-yl)methyl]-3-methylthiomethylazetidine-3-methanol hydrochloride | 1016233-55-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 1-[(9-deazaadenin-9-yl)methyl]-3-methylthiomethylazetidine-3-methanol hydrochloride
• 英文别名: [1-({4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl}methyl)-3-[(methylsulfanyl)methyl]azetidin-3-yl]methanol；[1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-3-(methylsulfanylmethyl)azetidin-3-yl]methanol
• CAS: 1016233-55-8
• 化学式: C₁₃H₁₉N₅OS
• 分子量: 293.393
• InChiKey: YYIVMSWPFALBOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  116
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  Tert-butyl 3-(hydroxymethyl)-3-(methylsulfanylmethyl)azetidine-1-carboxylate 在 盐酸 、 甲醇 、 水 、 sodium acetate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 3.08h， 生成 1-[(9-deazaadenin-9-yl)methyl]-3-methylthiomethylazetidine-3-methanol hydrochloride
  参考文献：
  名称：

  WO2008/79028

  摘要：

  公开号：

文献信息

• [EN] PROCESS FOR PREPARING IMMUCILLINS HAVING A METHYLENE LINK<br/>[FR] PROCÉDÉ DE PRÉPARATION D'IMMUCILLINES À LIAISON MÉTHYLÈNE
  申请人：IND RES LTD

  公开号：WO2009082247A1

  公开（公告）日：2009-07-02

  The invention relates to a process for preparing compounds that are inhibitors of nucleoside phosphorylases and nucleosidases, in particular, compounds that have a methylene link between a nucleoside base analogue moiety of the molecule and a sugar analogue moiety, via an amino nitrogen of the sugar analogue moiety.

  这项发明涉及一种制备核苷酸磷酸化酶和核苷酸酶抑制剂的方法，特别是一种具有核苷碱基类似物部分和糖类似物部分之间存在亚甲基连接的化合物，通过糖类似物部分的氨基氮。
• AZETIDINE ANALOGUES NUCLEOSIDASE AND PHOSPHORYLASE INHIBITORS
  申请人：Evans Gary Brian

  公开号：US20100168141A1

  公开（公告）日：2010-07-01

  Azetidine analogues of nucleosidase and nucleoside phosphorylase inhibitors having the general formula (I), the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, methods of treating certain diseases using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds wherein W and X are each independently selected from hydrogen, CH 2 OH, CH 2 OQ and CH 2 SQ; Y and Z are each independently selected from hydrogen, halogen, CH 2 OH, CH 2 OQ, CH 2 SQ, SQ, OQ and Q; Q is an alkyl, aralkyl or aryl group each of which may be optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy; R 1 is a radical of the formula (II) or R 1 is a radical of the formula (III) A is selected from N, CH and CR 2 , where R 2 is selected from halogen, alkyl, aralkyl, aryl, OH, NH 2 , NHR 3 , NR 3 R 4 and SR 5 , where R 3 , R 4 and R 5 are each alkyl, aralkyl or aryl groups optionally substituted with hydroxy or halogen, and where R 2 is optionally substituted with hydroxy or halogen when R 2 is alkyl, aralkyl or aryl; B is selected from hydroxy, NH 2 , NHR 6 , SH, hydrogen and halogen, where R 6 is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; D is selected from hydroxy, NH 2 , NHR 7 , hydrogen, halogen and SCH 3 , where R 7 is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; E is selected from N and CH; G is a C 1-4 saturated or unsaturated alkyl group optionally substituted with hydroxy or halogen, or G is absent; or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.

  具有通式（I）的核苷酸酶和核苷酸磷酸酶抑制剂的氮杂环类似物，以这些化合物作为药物，含有这些化合物的制药组合物，使用这些化合物治疗某些疾病的方法，制备这些化合物的方法，以及制备这些化合物有用的中间体，其中W和X各自独立地选自氢，CH2OH，CH2OQ和CH2SQ; Y和Z各自独立地选自氢，卤素，CH2OH，CH2OQ，CH2SQ，SQ，OQ和Q; Q是一种烷基，芳基或芳基烷基，每个基团可以选择性地取代一个或多个亲水基，卤素，甲氧基，氨基或羧基; R1是公式（II）的基团或R1是公式（III）的基团，其中A选自N，CH和CR2，其中R2选自卤素，烷基，芳基烷基，芳基，OH，NH2，NHR3，NR3R4和SR5，其中R3，R4和R5均为烷基，芳基烷基或芳基，可以选择性地取代亲水基或卤素，当R2为烷基，芳基烷基或芳基时，R2可以选择性地取代亲水基或卤素; B选自羟基，NH2，NHR6，SH，氢和卤素，其中R6是烷基，芳基烷基或芳基，可以选择性地取代亲水基或卤素; D选自羟基，NH2，NHR7，氢，卤素和SCH3，其中R7是烷基，芳基烷基或芳基，可以选择性地取代亲水基或卤素; E选自N和CH; G是C1-4饱和或不饱和烷基，可以选择性地取代亲水基或卤素，或者G不存在; 或其互变异构体，或其药学上可接受的盐，或其酯，或其前药。
• AZETIDINE ANALOGUES OF NUCLEOSIDASE AND PHOSPHORYLASE INHIBITORS
  申请人：Industrial Research Limited

  公开号：EP2114925A1

  公开（公告）日：2009-11-11
• US8283345B2
  申请人：——

  公开号：US8283345B2

  公开（公告）日：2012-10-09
• [EN] AZETIDINE ANALOGUES OF NUCLEOSIDASE AND PHOSPHORYLASE INHIBITORS<br/>[FR] ANALOGUES AZÉTIDINE D'INHIBITEURS DE NUCLÉOSIDASE ET DE PHOSPHORYLASE
  申请人：IND RES LTD

  公开号：WO2008079028A1

  公开（公告）日：2008-07-03

  [EN] Azetidine analogues of nucleosidase and nucleoside phosphorylase inhibitors having the general formula (I), the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, methods of treating certain diseases using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds wherein W and X are each independently selected from hydrogen, CH₂OH, CH₂OQ and CH₂SQ; Y and Z are each independently selected from hydrogen, halogen, CH₂OH, CH₂OQ, CH₂SQ, SQ, OQ and Q; Q is an alkyl, aralkyl or aryl group each of which may be optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy; R¹ is a radical of the formula (II) or R¹ is a radical of the formula (III) A is selected from N, CH and CR², where R² is selected from halogen, alkyl, aralkyl, aryl, OH, NH₂, NHR³, NR³R⁴ and SR⁵, where R³, R⁴ and R⁵ are each alkyl, aralkyl or aryl groups optionally substituted with hydroxy or halogen, and where R² is optionally substituted with hydroxy or halogen when R² is alkyl, aralkyl or aryl; B is selected from hydroxy, NH₂, NHR⁶, SH, hydrogen and halogen, where R⁶ is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; D is selected from hydroxy, NH₂, NHR⁷, hydrogen, halogen and SCH₃, where R⁷ is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; E is selected from N and CH; G is a C_1-4 saturated or unsaturated alkyl group optionally substituted with hydroxy or halogen, or G is absent; or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.
  [FR] L'invention porte sur des analogues azétidine d'inhibiteurs de nucléosidase et de nucléoside phosphorylase ayant la formule générale (I), sur l'utilisation de ces composés en tant que produits pharmaceutiques, sur des compositions pharmaceutiques contenant les composés, sur des procédés de traitement de certaines maladies à l'aide des composés, sur des procédés de préparation des composés, et sur des intermédiaires utiles dans la préparation des composés, W et X étant chacun indépendamment choisis parmi l'hydrogène, CH₂OH, CH₂OQ et CH₂SQ; Y et Z étant chacun indépendamment choisis parmi hydrogène, halogène, CH₂OH, CH₂OQ, CH₂SQ, SQ, OQ et Q; Q est un groupe alkyle, aralkyle ou aryle dont chacun peut être facultativement substitué par un ou plusieurs substituants choisis parmi hydroxy, halogène, méthoxy, amino ou carboxy; R¹ est un radical de la formule (II) ou R¹ est un radical de la formule (III); A est choisi parmi N, CH et CR², où R² est choisi parmi halogène, alkyle, aralkyle, aryle, OH, NH₂, NHR³, NR³R⁴ et SR⁵, où R³, R⁴ et R⁵ sont chacun un groupe alkyle, aralkyle ou aryle facultativement substitué par hydroxy ou halogène, et où R² est facultativement substitué par hydroxy ou halogène lorsque R² est alkyle, aralkyle ou aryle; B est choisi parmi hydroxy, NH₂, NHR⁶, SH, hydrogène et halogène, R⁶ étant un groupe alkyle, aralkyle ou aryle facultativement substitué par hydroxy ou halogène; D est choisi parmi hydroxy, NH₂, NHR⁷, hydrogène, halogène et SCH₃, R⁷ étant un groupe alkyle, aralkyle ou aryle facultativement substitué par hydroxy ou halogène; E est choisi parmi N et CH; G est un groupe alkyle saturé ou insaturé en C_1-4, facultativement substitué par hydroxy ou halogène, ou G est absent; ou un tautomère de ces composés, ou un sel pharmaceutiquement acceptable de ceux-ci, ou un ester de ceux-ci, ou un promédicament de ceux-ci.